Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar moko1987 (< 20) Submitted: 9/16/2009 1:53:44 AM : Outperform Start Price: $5.36 PGNX Score: +32.55

Great

Featured Broker Partners


Advertisement